Interview with Dr. Mark Cockett: Current Trends in Screening for Antiviral Therapeutics

Dr. Mark Cockett is Vice President of Infectious Diseases and Applied Genomics at Bristol-Myers Squibb (BMS). In this interview, we ask Dr. Cockett about considerations that major pharmaceutical companies such as BMS make when screening for and developing antiviral small molecule therapeutics. We di...

Descripción completa

Detalles Bibliográficos
Autores principales: Brahme, Nina N., Noblin, Devin J.
Formato: Texto
Lenguaje:English
Publicado: YJBM 2010
Materias:
Interview
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3002154/
https://www.ncbi.nlm.nih.gov/pubmed/21165343
_version_ 1782193699371876352
author Brahme, Nina N.
Noblin, Devin J.
author_facet Brahme, Nina N.
Noblin, Devin J.
author_sort Brahme, Nina N.
collection PubMed
description Dr. Mark Cockett is Vice President of Infectious Diseases and Applied Genomics at Bristol-Myers Squibb (BMS). In this interview, we ask Dr. Cockett about considerations that major pharmaceutical companies such as BMS make when screening for and developing antiviral small molecule therapeutics. We discuss the rationale behind an unbiased screening approach that led to recent published work identifying a hepatitis C-specific NS5A inhibitor. We conclude by asking about the emerging role of academia in antiviral drug discovery and future directions of pathogen drug discovery in general.
format Text
id pubmed-3002154
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher YJBM
record_format MEDLINE/PubMed
spelling pubmed-30021542010-12-16 Interview with Dr. Mark Cockett: Current Trends in Screening for Antiviral Therapeutics Brahme, Nina N. Noblin, Devin J. Yale J Biol Med Interview Dr. Mark Cockett is Vice President of Infectious Diseases and Applied Genomics at Bristol-Myers Squibb (BMS). In this interview, we ask Dr. Cockett about considerations that major pharmaceutical companies such as BMS make when screening for and developing antiviral small molecule therapeutics. We discuss the rationale behind an unbiased screening approach that led to recent published work identifying a hepatitis C-specific NS5A inhibitor. We conclude by asking about the emerging role of academia in antiviral drug discovery and future directions of pathogen drug discovery in general. YJBM 2010-12 2010-12 /pmc/articles/PMC3002154/ /pubmed/21165343 Text en Copyright ©2010, Yale Journal of Biology and Medicine https://creativecommons.org/licenses/by-nc/3.0/This is an open access article distributed under the terms of the Creative Commons CC BY-NC license, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited. You may not use the material for commercial purposes.
spellingShingle Interview
Brahme, Nina N.
Noblin, Devin J.
Interview with Dr. Mark Cockett: Current Trends in Screening for Antiviral Therapeutics
title Interview with Dr. Mark Cockett: Current Trends in Screening for Antiviral Therapeutics
title_full Interview with Dr. Mark Cockett: Current Trends in Screening for Antiviral Therapeutics
title_fullStr Interview with Dr. Mark Cockett: Current Trends in Screening for Antiviral Therapeutics
title_full_unstemmed Interview with Dr. Mark Cockett: Current Trends in Screening for Antiviral Therapeutics
title_short Interview with Dr. Mark Cockett: Current Trends in Screening for Antiviral Therapeutics
title_sort interview with dr. mark cockett: current trends in screening for antiviral therapeutics
topic Interview
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3002154/
https://www.ncbi.nlm.nih.gov/pubmed/21165343
work_keys_str_mv AT brahmeninan interviewwithdrmarkcockettcurrenttrendsinscreeningforantiviraltherapeutics
AT noblindevinj interviewwithdrmarkcockettcurrenttrendsinscreeningforantiviraltherapeutics

Ejemplares similares